Published in Medical Letter on the CDC and FDA, June 5th, 2005
According to IMS, sales of Esmolol 10 mg/mL were $16.5 million in 2004. APP expects to commence marketing this product immediately.
Esmolol is the fourth product approval APP has received in 2005.
Esmolol is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.